Blackstone Group, as it aims to focus on developing drugs for unmet medical needs and rare diseases. Japan's largest pharmaceuticals company has been sellingits over-the-counter (OTC) assets worldwide as it seeks to refocus its business and reduce debt following a $59 billion acquisition of Shire Plc last year.Takeda CEO Christophe Weber said via an online briefing the company had decided to sell the Japanese OTC unit because it would be difficult for Takeda to keep investing in OTC businesses while trying to develop new drugs for more serious diseases."My responsibility is to make sure that we don't destroy value (for OTC businesses) but create value, and to create value we need to grow businesses and it's not good to keep business and not.